Cargando…
Imatinib Mesylate Reduces Neurotrophic Factors and pERK and pAKT Expression in Urinary Bladder of Female Mice With Cyclophosphamide-Induced Cystitis
Imatinib mesylate is a tyrosine kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR)-α, -β, stem cell factor receptor (c-KIT), and BCR-ABL. PDGFRα is expressed in a subset of interstitial cells in the lamina propria (LP) and detrusor muscle of the urinary bladder. PDGFRα +...
Autores principales: | Perkins, Megan, Girard, Beatrice M., Campbell, Susan E., Hennig, Grant W., Vizzard, Margaret A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072830/ https://www.ncbi.nlm.nih.gov/pubmed/35528149 http://dx.doi.org/10.3389/fnsys.2022.884260 |
Ejemplares similares
-
Imatinib Mesylate Reduces Voiding Frequency in Female Mice With Acute Cyclophosphamide-Induced Cystitis
por: Perkins, Megan E., et al.
Publicado: (2022) -
pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma
por: Li, Jun, et al.
Publicado: (2015) -
Loss of Bmp2 impairs odontogenesis via dysregulating pAkt/pErk/GCN5/Dlx3/Sp7
por: Chen, Shuo, et al.
Publicado: (2023) -
Changes in nerve growth factor signaling in female mice with cyclophosphamide-induced cystitis
por: Hsiang, Harrison W., et al.
Publicado: (2023) -
Clinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy
por: LIU, WENJUAN, et al.
Publicado: (2015)